Meeting
2023 ASCO Annual Meeting
A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
Authors
Guang-Hai Dai
Senior Department of Oncology, the 5th Medical Center of the PLA General Hospital, Beijing, China
Guang-Hai Dai , Ru Jia , Haiyan Si , Zhi-Kuan Wang , Guo-Chao Deng , Nan Zhang , Fang-Fang Liu , Yue Shi , Yao-Yue Zhang , Yu-Shan Jia , Bei Zhang , Shuang Tong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT05218889
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4142)
DOI
10.1200/JCO.2023.41.16_suppl.4142
Abstract #
4142
Poster Bd #
463
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Ru Jia
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Dong-Sheng Zhang
Poster
2018 Gastrointestinal Cancers Symposium
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Daniel John Renouf
Poster
2017 ASCO Annual Meeting
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Philippa Corrie